AI takes on liver cancer: could a computer help pick the right immunotherapy?

NCT ID NCT07729618

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 hospitals will be enrolled. Hospitals are randomly assigned to either use the AI tool or follow standard decision-making. The AI provides estimates and rankings of appropriate ICI options, but the final choice remains with the care team. The main goal is to see if AI-assisted selection improves progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an artificial intelligence clinical decision-support system
What this could lead to
If it works, this could help doctors personalize immunotherapy choices for advanced liver cancer, potentially improving survival and quality of life.
What could go wrong
The AI is only advisory and may not outperform standard decision-making. The trial is large but pragmatic, so results may vary across hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.